Tag: MONOGRAPH

  • Tretinoin

    Endogenous retinoid and pan-retinoic acid receptor agonist with genomic transcriptional regulation

    The principal biologically active metabolite of vitamin A, functioning as a pan-RAR agonist that regulates epithelial differentiation, collagen biosynthesis, and myeloid cell maturation, with established clinical applications spanning topical dermatology, photoaging reversal, and systemic differentiation therapy of acute promyelocytic leukemia.

    Abstract

    Tretinoin (all-trans-retinoic acid, ATRA) is the carboxylic acid form of vitamin A and the principal endogenous ligand of the nuclear retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma), through which it regulates the transcription of over 500 target genes involved in cellular differentiation, proliferation, apoptosis, and immune modulation. First isolated and characterized in the mid-twentieth century as a metabolite of retinol, tretinoin was developed as a topical dermatological agent by Albert Kligman and James Fulton at the University of Pennsylvania in the 1960s and received United States Food and Drug Administration approval for acne vulgaris in 1971, making it the first retinoid approved for clinical use. The compound was subsequently approved for the treatment of fine facial wrinkles and mottled hyperpigmentation associated with photoaging in 1995. The molecular pharmacology of tretinoin is mediated through ligand-dependent activation of RAR/RXR heterodimers bound to retinoic acid response elements in target gene promoters; in the unliganded state, these heterodimers recruit corepressor complexes (NCoR, SMRT) and histone deacetylases that maintain transcriptional silencing, while tretinoin binding induces conformational change, corepressor release, and coactivator recruitment with histone acetyltransferase activity, resulting in chromatin remodeling and transcriptional activation. In the dermatological context, this transcriptional program promotes keratinocyte differentiation, accelerates corneocyte shedding, inhibits comedone formation, stimulates type I procollagen synthesis, and blocks ultraviolet-induced matrix metalloproteinase activation through inhibition of activator protein 1. In APL, pharmacological concentrations of tretinoin overcome the dominant-negative transcriptional repression imposed by the PML-RAR-alpha fusion protein, driving terminal granulocytic differentiation of the leukemic clone.

    Pharmacokinetics differ substantially between the topical and systemic routes. Topical application produces minimal systemic absorption, with percutaneous bioavailability estimated at less than 2 percent and negligible alteration of endogenous plasma retinoid concentrations. The terminal elimination half-life is short (0.5 to 2 hours) and is dominated by oxidative metabolism through CYP26A1, CYP2C8, and CYP3A4, with a clinically significant autoinduction phenomenon: tretinoin potently upregulates CYP26A1 transcription through retinoic acid response elements in the CYP26A1 promoter, resulting in progressive acceleration of its own clearance such that plasma concentrations decline to approximately one-third of initial values within one week of continuous dosing at constant dose. This autoinduction has clinical implications for APL treatment duration and has motivated intermittent dosing schedules and combination regimens with arsenic trioxide. The compound is teratogenic through disruption of retinoic acid gradient signaling during embryogenesis, classified as FDA pregnancy category X for systemic use; topical tretinoin, by contrast, does not produce measurable increases in systemic retinoid exposure and is not associated with increased teratogenic risk in epidemiological studies, though precautionary avoidance during pregnancy is recommended. The principal systemic toxicity in APL therapy is the differentiation syndrome (formerly retinoic acid syndrome), a potentially fatal inflammatory response occurring in approximately 25 percent of treated patients and characterized by fever, dyspnea, weight gain, pulmonary infiltrates, and pleural or pericardial effusions, managed with early recognition and high-dose corticosteroids.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 2-Bromo-LSD

    Non-hallucinogenic lysergamide serotonin receptor modulator with biased 5-HT2A partial agonism and 5-HT1 pan-agonism

    A brominated lysergic acid diethylamide derivative originally synthesized by Hofmann and Troxler in 1957, distinguished from the parent compound LSD by non-hallucinogenic biased partial agonism at the serotonin 5-HT2A receptor, antagonism at the cardiotoxicity-associated 5-HT2B receptor, potent 5-HT1 pan-agonism, and emerging therapeutic interest in cluster headache prophylaxis and rapid-acting antidepressant development.

    Abstract

    2-Bromo-lysergic acid diethylamide (2-Br-LSD; BOL-148; CAS 478-84-2), the 2-bromo derivative of lysergic acid diethylamide (LSD), is a non-hallucinogenic lysergamide serotonin receptor modulator first synthesized by Franz Troxler and Albert Hofmann at Sandoz in 1957 as part of a systematic structure-activity exploration of ergoline pharmacology. The compound binds with high affinity to the same serotonin, dopamine, and adrenergic receptor targets as LSD but exhibits a fundamentally different functional profile: at the serotonin 5-HT2A receptor, 2-Br-LSD acts as a biased partial agonist with an Emax of approximately 60 percent of the serotonin reference response (compared to approximately 92 percent for LSD), weak beta-arrestin recruitment (Emax approximately 37 percent), and no induction of the head-twitch response in mice across a 100-fold dose range, the accepted rodent behavioral proxy for human hallucinogenic activity. At the serotonin 5-HT2B receptor, 2-Br-LSD acts as an antagonist, eliminating the cardiac valvulopathy liability that constrains chronic dosing of LSD and other ergoline agonists at this target. Across the 5-HT1 receptor family (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), the compound demonstrates potent pan-agonism, engaging the established anti-migraine drug targets 5-HT1B, 5-HT1D, and 5-HT1F at sub-nanomolar to low-nanomolar functional concentrations.

    The therapeutic interest in 2-Br-LSD spans two principal domains. The second is rapid-acting antidepressant activity, supported by the Lewis et al. (2023) characterization in Cell Reports demonstrating that 2-Br-LSD promotes dendritogenesis and spinogenesis in primary rat cortical neurons at 1 to 10 micromolar concentrations (comparable to ketamine), reverses chronic variable stress-induced behavioral deficits in mice with effects persisting at least 28 days after a four-dose regimen, and does so through a 5-HT2A-dependent mechanism confirmed by volinanserin blockade both in vitro and in vivo. The compound does not produce tolerance on seven-day repeated dosing, in contrast to classical psychedelics that produce rapid tachyphylaxis.

    Multiple pharmaceutical development programs are active. BetterLife Pharma is advancing BETR-001 (2-Br-LSD) through IND-enabling studies for major depressive disorder and cluster headache, with FDA pre-IND feedback received in January 2022 confirming suitability of the development program for IND filing. Seaport Therapeutics is developing SPT-348 (Glyph2BLSD), an oral prodrug of 2-Br-LSD, for treatment-resistant depression and post-traumatic stress disorder, with first-in-human-enabling studies underway. Cryo-electron microscopy structures of the 5-HT2A receptor bound to 2-Br-LSD in complex with mini-Gq protein (PDB 9AS0; Gumpper, Fay, Roth) have elucidated the structural basis of its biased partial agonism and provide a molecular template for next-generation non-hallucinogenic psychoplastogen design.

    Pharmacokinetics in mice demonstrate rapid absorption (Tmax 0.2 hours in plasma, 0.17 hours in brain), brain penetrance (brain-to-plasma ratio 0.27 to 0.75), and short central nervous system residence (brain half-life 0.7 to 1.3 hours, below detection at 4 hours). The compound is not scheduled in the United States, Canada, Germany, or the European Union. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • DNL343

    Small molecule eukaryotic initiation factor 2B (eIF2B) activator and integrated stress response (ISR) inhibitor

    A potent, selective, CNS-penetrant bicyclo[1.1.1]pentane-centered eIF2B activator developed by Denali Therapeutics for the suppression of aberrant integrated stress response signaling in neurodegenerative disease, advanced through Phase 2/3 clinical evaluation in amyotrophic lateral sclerosis.

    Abstract

    DNL343 is a first-in-class, orally bioavailable, brain-penetrant small molecule activator of eukaryotic initiation factor 2B (eIF2B), the guanine nucleotide exchange factor that governs the rate-limiting step in translation initiation and serves as the principal regulatory node of the integrated stress response (ISR). The compound was designed at Denali Therapeutics as an improvement over the prototype tool compound ISRIB, which despite landmark demonstrations of cognitive enhancement and neuroprotection in rodent models suffered from poor aqueous solubility, limited oral bioavailability, and pharmaceutical intractability [1, 2]. DNL343 retains the symmetric bis-glycolamide pharmacophore that stabilizes the eIF2B decameric complex at the subunit interface but replaces the central cyclohexane of ISRIB with a bicyclo[1.1.1]pentane (BCP) bioisostere, conferring improved solubility, metabolic stability, and CNS penetration [3]. The compound displays an IC50 of 3.2 nanomolar in a cellular ATF4 reporter assay, a brain-to-plasma unbound concentration ratio of approximately 0.8 in rat, and a plasma elimination half-life of 31 to 46 hours in healthy human subjects, supporting once-daily oral dosing [3, 4, 5].

    Preclinically, DNL343 produced dose-dependent neuroprotection in an optic nerve crush model of acute retinal ganglion cell degeneration and, in the Eif2b5 R191H knock-in mouse model of vanishing white matter disease (a genetic ISR-driven leukoencephalopathy), restored body weight, normalized motor function, reversed ISR transcriptional signatures, normalized plasma neurofilament light chain (NfL), and extended survival from 25 percent to 84.6 percent of treated animals when administered therapeutically at advanced disease stages [1]. In inducible TDP-43 proteinopathy mouse models relevant to amyotrophic lateral sclerosis (ALS), DNL343 attenuated ISR activation and reduced markers of neurodegeneration [6].

    The compound was subsequently advanced to Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, a 24-week randomized, placebo-controlled study enrolling 186 participants on DNL343 and 139 on placebo. In January 2025, Denali Therapeutics announced that the trial did not meet its primary endpoint of slowing disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival, and key secondary endpoints including muscle strength and respiratory function showed no statistical separation from placebo [9, 10]. A subsequent SEC filing revealed that DNL343 did not alter NfL biomarker levels over the treatment period [10]. The compound is no longer in active clinical development for ALS.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Magnesium

    Essential divalent cation and enzymatic cofactor with voltage-dependent NMDA receptor antagonism and broad physiological regulatory activity

    An essential mineral element required as a cofactor in over 600 enzymatic reactions, distinguished by its voltage-dependent block of the NMDA receptor ion channel, its role in cellular energy metabolism through ATP chelation, and its broad clinical evidence base spanning cardiovascular, neurological, musculoskeletal, and metabolic indications.

    Abstract

    Magnesium (Mg2+) is the second most abundant intracellular cation, the fourth most abundant cation in the human body, and an essential cofactor in more than 600 enzymatic reactions encompassing DNA and RNA synthesis, protein synthesis, cellular energy metabolism, ion channel regulation, and neuromuscular function. Total body magnesium in the adult human is approximately 24 to 29 grams, of which approximately 60 percent resides in bone mineral, 39 percent in intracellular soft tissue compartments, and less than 1 percent in extracellular fluid and plasma. Serum magnesium concentration in healthy adults is maintained within a narrow physiological range of 0.75 to 0.95 millimoles per liter through coordinated intestinal absorption, renal reabsorption, and osseous exchange, with the transient receptor potential melastatin channels TRPM6 and TRPM7 serving as the principal apical magnesium entry pathways in intestinal and renal epithelial cells. The molecular pharmacology of magnesium is anchored by its voltage-dependent block of the N-methyl-D-aspartate (NMDA) receptor ion channel, a mechanism through which extracellular Mg2+ occupies a binding site within the channel pore at resting membrane potential and is expelled upon postsynaptic depolarization, thereby gating calcium influx and serving as a coincidence detector for synaptic plasticity. This NMDA receptor interaction, together with magnesium’s roles as a physiological calcium antagonist, a modulator of potassium and sodium channel conductance, and a required cofactor for ATP-dependent kinase and phosphatase reactions, underlies the broad clinical pharmacology of the element across neurological, cardiovascular, musculoskeletal, and metabolic systems. Subclinical magnesium deficiency is increasingly recognized as a prevalent and underdiagnosed condition, with epidemiological surveys indicating that approximately 50 to 80 percent of adults in industrialized nations consume less than the estimated average requirement. The clinical consequences of chronic marginal magnesium status include increased risk of hypertension, type 2 diabetes mellitus, metabolic syndrome, coronary artery disease, stroke, migraine, depression, and osteoporosis. Magnesium is available in numerous supplemental salt forms that differ substantially in elemental magnesium content, solubility, bioavailability, and tissue distribution. Organic salts (citrate, glycinate, taurate, malate, threonate) demonstrate superior bioavailability compared to inorganic forms (oxide, hydroxide, carbonate, sulfate) in human pharmacokinetic studies. Magnesium L-threonate has attracted particular research interest for its capacity to elevate brain magnesium concentrations through blood-brain barrier penetration via glucose transporters, with randomized controlled trials demonstrating significant improvements in cognitive performance and working memory. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tributyrin

    Triglyceride prodrug of butyric acid with histone deacetylase inhibitory activity

    A glycerol tributyrate ester functioning as a stable, orally bioavailable prodrug of butyric acid, distinguished from other butyrate delivery forms by its resistance to gastric degradation, intracellular lipase-mediated release of three butyrate equivalents, and HDAC-inhibitory activity supporting applications in oncology chemoprevention, intestinal barrier maintenance, hepatoprotection, metabolic inflammation, and skeletal muscle differentiation.

    Abstract

    Tributyrin (glycerol tributyrate, CAS 60-01-5) is the 1,2,3-tributanoyl ester of glycerol and the principal triglyceride prodrug of butyric acid studied in human clinical pharmacology and preclinical oncology. Classified by the United States Food and Drug Administration as Generally Recognized as Safe (GRAS) for food use, tributyrin is a naturally occurring lipid constituent of bovine milk fat and honey that has attracted sustained research interest as a vehicle for delivering pharmacologically active butyrate concentrations to systemic circulation and to the colonic epithelium, overcoming the rapid first-pass hepatic clearance, objectionable odor, and poor oral bioavailability that limit the therapeutic application of free butyric acid and its sodium salt.

    The molecular pharmacology of tributyrin is mediated through its hydrolytic product, butyrate, a four-carbon short-chain fatty acid that operates through at least three characterized molecular mechanisms: inhibition of class I and class II histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3; agonism at the G-protein-coupled receptor GPR109A (also designated HCAR2 or HM74a), the niacin receptor expressed on colonocytes, adipocytes, and immune cells; and agonism at the free fatty acid receptors GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells and immune cells. The HDAC-inhibitory activity produces histone hyperacetylation, chromatin remodeling, and consequent transcriptional activation of tumor suppressor genes (p21WAF1/CIP1, BAX, p53), cell cycle arrest proteins, and differentiation-associated gene programs in neoplastic cells. The GPR109A agonism mediates anti-inflammatory signaling through suppression of NF-kappaB-dependent proinflammatory cytokine production and through promotion of regulatory T-cell and M2-macrophage phenotypes in adipose tissue and intestinal lamina propria.

    Two Phase I clinical trials in patients with advanced solid tumors have characterized the human pharmacology of tributyrin. Both trials confirmed that tributyrin is well tolerated, with mild gastrointestinal complaints (nausea, eructation, diarrhea) as the principal adverse events.

    Preclinical pharmacology spans oncology, gastroenterology, hepatology, metabolic disease, and muscle biology. In oncology, tributyrin induces differentiation, growth arrest, and apoptosis in human prostate cancer (PC3, LNCaP, TSU-Pr1), colon cancer (HT-29, Caco-2), breast cancer (MCF-7), and leukemia cell lines at concentrations of 0.1 to 4 mM, and suppresses hepatocarcinogenesis in the resistant hepatocyte rat model through p53 acetylation and activation of the p53 apoptotic signaling pathway. In gastroenterology, tributyrin maintains intestinal tight junction integrity, reduces antibiotic-induced intestinal injury in combination with Lactobacillus GG, and mitigates chronic-binge ethanol-induced intestinal barrier disruption and liver injury. In metabolic disease, tributyrin attenuates obesity-associated inflammation, improves insulin responsiveness, and reduces hepatic triglyceride accumulation through a GPR109A-dependent mechanism. In muscle biology, dietary tributyrin promotes satellite cell terminal differentiation through HDAC inhibition and epigenetic priming, producing measurable increases in muscle fiber cross-sectional area in neonatal piglet models.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 78c

    Thiazoloquin(az)olin(on)e small-molecule CD38 NADase inhibitor

    A potent, specific, reversible, and uncompetitive small-molecule inhibitor of the NAD+ glycohydrolase CD38, developed from a thiazoloquinolin(on)e medicinal chemistry series and distinguished by low-nanomolar potency, oral bioavailability, and demonstrated reversal of age-related tissue NAD+ decline with extension of lifespan and healthspan in murine aging models.

    Abstract

    Compound 78c (CD38-IN-78c; CAS 1700637-55-3) is a thiazoloquinolin(on)e small molecule identified as the lead compound from a structure-activity exploration of CD38 inhibitors reported by Haffner, Bhatt, and colleagues in 2015. It is a potent, specific, reversible, and uncompetitive inhibitor of the ectoenzyme CD38 (cluster of differentiation 38), a type II transmembrane glycoprotein with NAD+ glycohydrolase, ADP-ribosyl cyclase, and cyclic ADP-ribose hydrolase activities, with half-maximal inhibitory concentration (IC50) values of 7.3 nM against human CD38 and 1.9 nM against murine CD38, and an inhibition constant (Ki) of 8.4 nM. The compound is cell-permeable, orally bioavailable in rodent species, and non-toxic at pharmacologically active doses in chronic administration studies extending to 20 months. CD38 has been identified as the principal enzyme responsible for age-related tissue NAD+ decline, a process that contributes to mitochondrial dysfunction, impaired sirtuin signaling, metabolic derangement, and the progressive physiological deterioration characteristic of aging. By inhibiting CD38-mediated degradation of NAD+ and its biosynthetic precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), compound 78c elevates tissue NAD+ levels (greater than 5-fold in liver and greater than 1.2-fold in skeletal muscle in diet-induced obese mice at a 2-hour time point) and thereby restores the activity of NAD+-dependent enzymes including sirtuins 1, 3, and 6 and poly(ADP-ribose) polymerases.

    The landmark 2018 publication by Tarrago, Chini, and colleagues in Cell Metabolism demonstrated that chronic oral administration of 78c to naturally aged mice and to Cockayne syndrome progeroid mice reverses age-related NAD+ decline and improves glucose tolerance, exercise capacity, muscle function, and cardiac function. A follow-up 2022 study by Peclat and colleagues in Aging Cell extended these findings to chronological aging, reporting that 78c increases median lifespan by approximately 10 percent, extends maximal lifespan, and improves multiple healthspan parameters including treadmill endurance, grip strength, body composition, and metabolic markers in naturally aged C57BL/6 mice, with sex-dependent differences in the magnitude of benefit. Additional preclinical studies have demonstrated cardioprotection against ischemia-reperfusion injury through preservation of tetrahydrobiopterin (BH4) and endothelial nitric oxide synthase coupling; anti-inflammatory activity through suppression of NF-kappaB-dependent cytokine expression (IL-1beta, IL-6, TNF-alpha) in macrophages and microglia; therapeutic efficacy in collagen-induced arthritis through restoration of regulatory T cell populations and immune balance; and attenuation of osteoclastogenesis and inflammatory bone resorption. The compound does not cross the blood-brain barrier at appreciable concentrations but exerts systemic anti-inflammatory and metabolic effects relevant to age-related neurodegeneration through peripheral NAD+ homeostasis.

    Compound 78c has not entered human clinical trials. It is supplied by multiple research chemical vendors at greater than 98 percent purity as a research tool compound. The current research state is one of strong and replicable preclinical efficacy across aging, cardiovascular, inflammatory, and metabolic disease models, with absent clinical pharmacokinetic and safety data in humans. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Empagliflozin

    Selective sodium-glucose co-transporter 2 (SGLT2) inhibitor of the C-aryl glucoside structural class

    A highly selective SGLT2 inhibitor developed by Boehringer Ingelheim as an oral antihyperglycemic agent, distinguished from other gliflozins by the highest SGLT2-to-SGLT1 selectivity ratio in the class, landmark cardiovascular and renal outcome trial data, and regulatory approval across type 2 diabetes, heart failure with reduced and preserved ejection fraction, and chronic kidney disease.

    Abstract

    Empagliflozin (BI 10773, marketed as Jardiance) is a potent, orally bioavailable, selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) protein expressed in the S1 and S2 segments of the renal proximal tubule, where it mediates approximately 90 percent of filtered glucose reabsorption. The compound is a C-aryl glucoside bearing a chlorophenyl core linked to a tetrahydrofuranyloxy-substituted benzyl moiety, and it exhibits the highest selectivity for SGLT2 over the intestinal isoform SGLT1 among the marketed gliflozins, with a selectivity ratio exceeding 2500-fold in heterologous expression systems. Empagliflozin was developed by Boehringer Ingelheim in collaboration with Eli Lilly and Company, received initial regulatory approval in 2014 for the treatment of type 2 diabetes mellitus, and has since undergone one of the most consequential clinical development programs in modern cardiometabolic medicine. The EMPA-REG OUTCOME trial (2015), enrolling 7020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 35 percent reduction in hospitalization for heart failure, results that fundamentally altered the treatment paradigm for type 2 diabetes and prompted regulatory label expansions for cardiovascular risk reduction. The EMPEROR-Reduced trial (2020) demonstrated a 25 percent reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction regardless of diabetes status, while the EMPEROR-Preserved trial (2021) extended this benefit to patients with heart failure and preserved ejection fraction, a population for which few prior therapies had demonstrated efficacy. The EMPA-KIDNEY trial (2022) demonstrated a 28 percent reduction in the composite of kidney disease progression or cardiovascular death in 6609 patients with chronic kidney disease across a broad range of eGFR values. Pharmacokinetics are characterized by rapid oral absorption with peak plasma concentrations at approximately 1.5 hours, steady-state plasma protein binding of 80 to 86 percent, a terminal elimination half-life of approximately 12.4 hours supporting once-daily dosing, and metabolism predominantly through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 without clinically meaningful cytochrome P450 involvement. The compound has minimal drug-drug interaction potential and does not require dose adjustment for hepatic impairment or mild-to-moderate renal impairment, although efficacy on glycemic endpoints diminishes at lower eGFR values where the filtered glucose load is reduced. The principal adverse events are genital mycotic infections (occurring in approximately 5 to 10 percent of female patients and 1 to 5 percent of male patients), urinary tract infections, volume depletion (particularly in elderly patients and those on concomitant diuretics), and rare but serious events including euglycemic diabetic ketoacidosis and necrotizing fasciitis of the perineum (Fournier gangrene). This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mirogabalin

    Selective alpha-2-delta-1 subunit ligand of voltage-gated calcium channels (gabapentinoid)

    A next-generation gabapentinoid developed by Daiichi Sankyo with preferential binding and prolonged dissociation kinetics at the alpha-2-delta-1 subunit of voltage-gated calcium channels, approved in Japan and select Asian jurisdictions for peripheral neuropathic pain and distinguished from pregabalin and gabapentin by subunit selectivity and a potentially wider therapeutic margin.

    Abstract

    Mirogabalin (DS-5565) is a novel gabapentinoid analgesic that binds with high affinity and selectivity to the alpha-2-delta-1 (alpha2delta-1) subunit of voltage-gated calcium channels (VGCCs), developed by Daiichi Sankyo Company and approved in Japan in January 2019 for the treatment of peripheral neuropathic pain associated with diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN). The compound is marketed as Tarlige in oral tablet formulation and has subsequently received regulatory approval in Taiwan (2020) and Thailand (2022) for peripheral neuropathic pain indications. Unlike the first-generation gabapentinoids gabapentin and pregabalin, which bind nonselectively to both alpha2delta-1 and alpha2delta-2 subunits with comparable affinity and dissociation kinetics, mirogabalin demonstrates preferential binding to the alpha2delta-1 subunit with a dissociation half-life of approximately 11.1 hours at alpha2delta-1 versus 2.4 hours at alpha2delta-2 in human recombinant systems. This kinetic selectivity is hypothesized to confer a favorable ratio of analgesic efficacy (mediated principally through alpha2delta-1 in dorsal root ganglia and spinal cord dorsal horn) to central nervous system adverse effects (mediated in part through alpha2delta-2 in cerebellar Purkinje neurons and other central structures), although this hypothesis has not been formally validated in controlled comparative clinical trials against pregabalin at equipotent analgesic doses.

    A separate Phase 3 program evaluated mirogabalin for central neuropathic pain after spinal cord injury in a multinational Asian trial. In contrast, the global Phase 3 ALDAY program for fibromyalgia pain, consisting of three large randomized trials enrolling more than 3,600 subjects in the United States and Europe, failed to meet the primary efficacy endpoint in all three studies; mirogabalin did not demonstrate statistically significant superiority over placebo for reduction in worst daily pain score at week 13 in fibromyalgia, and the fibromyalgia development program was subsequently discontinued. The compound is not approved by the United States Food and Drug Administration or the European Medicines Agency.

    Pharmacokinetically, mirogabalin is rapidly and nearly completely absorbed after oral administration with a time to peak plasma concentration of approximately 1 hour. The compound undergoes limited hepatic metabolism (13 to 20 percent of administered dose) through uridine 5-prime-diphospho-glucuronosyltransferase (UGT) isoforms, with the majority of the dose (61 to 72 percent) excreted unchanged in urine. Renal clearance exceeds glomerular filtration rate, indicating active tubular secretion. Dose adjustment is required in patients with renal impairment. The principal adverse events are somnolence, dizziness, peripheral edema, and weight gain, consistent with the gabapentinoid class but reported at generally lower incidence than pregabalin at comparable analgesic doses in some observational comparisons.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • TRV045

    Selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist with sustained signaling and absence of receptor desensitization or lymphocyte sequestration

    A selective S1P1 receptor agonist developed by Trevena as a non-opioid treatment for diabetic neuropathic pain, distinguished from fingolimod-class functional antagonists by sustained receptor activation without S1P1R desensitization, protein downregulation, or peripheral lymphocyte depletion, and with additional preclinical evidence for anti-seizure activity.

    Abstract

    TRV045 (CAS 2256030-24-5) is a novel, orally bioavailable, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist under clinical development by Trevena, Inc. as a potential non-opioid treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy and, through a collaboration with the National Institutes of Health, as a potential treatment for epilepsy. The compound is distinguished from the approved S1P receptor modulator class (fingolimod, siponimod, ozanimod, ponesimod) by a pharmacological mechanism that produces sustained S1P1R agonism without the receptor internalization, functional desensitization, or S1P1R protein downregulation that characterizes fingolimod and related agents. The practical consequence of this mechanistic differentiation is the absence of peripheral lymphocyte sequestration (lymphopenia), the absence of first-dose bradycardia and atrioventricular conduction delay, and the absence of the immunosuppressive liability that defines the approved S1P modulator class and limits its application outside multiple sclerosis. Effects were sustained over 14 days of repeated dosing without evidence of tolerance, receptor desensitization, or S1P1R protein reduction in spinal cord tissue. In contrast, fingolimod in the same CIPN model produced approximately 70 percent reduction in S1P1R functional activity and 30 percent protein reduction. In human Phase 1 clinical studies, TRV045 has been evaluated in three completed trials comprising a first-in-human single and multiple ascending dose study in 89 healthy volunteers, a target engagement proof-of-concept study using the capsaicin-induced pain (PainCart) model in 25 healthy subjects, and a transcranial magnetic stimulation (TMS) and electroencephalography (EEG) proof-of-concept study in 25 healthy male subjects. Across all three completed Phase 1 studies, TRV045 demonstrated a favorable tolerability profile with no serious adverse events, no drug-related discontinuations, no clinically significant lymphopenia, no bradycardia, no blood pressure changes, and no prolongation of QTcF or PR intervals. The most common adverse events were mild headache, somnolence, dizziness, and fatigue. Trevena is advancing an optimized oral formulation through clinical pharmacokinetic evaluation in preparation for Phase 2 development. TRV045 is an investigational compound not approved by the United States Food and Drug Administration. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • AAZ-A-154

    Non-hallucinogenic psychoplastogen; isotryptamine-derived 5-HT2A receptor partial agonist with neuroplasticity-promoting activity

    A non-hallucinogenic isotryptamine psychoplastogen discovered via engineered 5-HT2A biosensor screening at UC Davis, producing rapid and sustained antidepressant-like effects through serotonin receptor-mediated structural neuroplasticity without psychedelic, dissociative, or psychotomimetic activity.

    Abstract

    AAZ-A-154, subsequently designated DLX-001 and assigned the international nonproprietary name zalsupindole, is a substituted isotryptamine derivative that acts as a low-potency, low-efficacy partial agonist of the serotonin 5-HT2A receptor (EC50 approximately 8,200 nM; Emax approximately 17 percent of serotonin maximum) and a moderate-efficacy partial agonist of the 5-HT2C receptor (EC50 approximately 3,300 nM; Emax approximately 70 percent), with silent antagonism at the 5-HT2B receptor and selectivity for serotonergic over dopaminergic, adrenergic, and opioid targets. The compound was first synthesized in 2019 in the laboratory of David E. Olson at the University of California, Davis, and was identified from a library screen using psychLight, a genetically encoded fluorescent biosensor constructed from the human 5-HT2A receptor with a circularly permuted green fluorescent protein inserted into the third intracellular loop [1]. PsychLight discriminated hallucinogenic from non-hallucinogenic 5-HT2A ligands on the basis of differential conformational activation signatures, and AAZ-A-154 was selected as a lead compound on the basis of its favorable ligand score, a metric that predicted non-hallucinogenic character despite retention of 5-HT2A-dependent psychoplastogenic activity.

    The compound is structurally related to 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) but is an isotryptamine (the aminoalkyl side chain is attached to the indole nitrogen at position 1 rather than at position 3), a modification that repositions the compound in chemical space outside classical psychedelic tryptamines. The (R)-enantiomer is the active form; the alpha-methyl substituent on the aminoalkyl chain confers metabolic stability and enantioselective receptor engagement. The compound increased dendritic arbor complexity in cultured embryonic rat cortical neurons to a degree comparable to ketamine, and the neuroplastogenic effect was abolished by the 5-HT2 receptor antagonist ketanserin, confirming receptor dependence [1].

    A comprehensive preclinical characterization published by Agrawal et al. (2025) in ACS Chemical Neuroscience demonstrated that zalsupindole promoted cortical neuritogenesis in vitro, increased dendritic spine density in the prefrontal cortex in vivo, and enhanced measures of functional plasticity to a degree comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine, despite lacking any of the acute cellular and behavioral characteristics of hallucinogenic or dissociative compounds [2]. Pharmacokinetic studies revealed high brain penetrance, rapid distribution, and rapid clearance. A Phase 1b study in 18 adults with major depressive disorder reported clinically meaningful reductions in Montgomery-Asberg Depression Rating Scale scores of approximately 12 points (approximately 50 percent improvement) by Day 8, with effects maintained through Day 36, and comparable efficacy between a seven-day once-daily regimen and a two-dose regimen [5]. No serious adverse events were reported across more than 120 individuals studied. Dose-dependent nausea, headache, and dizziness were the principal mild adverse events. In October 2025, the United States Food and Drug Administration cleared the Investigational New Drug application for a Phase 2, multi-site, randomized, double-blind, placebo-controlled trial in major depressive disorder featuring at-home self-administration [5]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.